课题基金 / 基金详情

Development of Novel Immune Checkpoint Blockade Therapies in Mouse Models of Invasive Lobular Breast Carcinoma

Development of Novel Immune Checkpoint Blockade Therapies in Mouse Models of Invasive Lobular Breast Carcinoma
在侵袭性小叶乳腺癌小鼠模型中开发新型免疫检查点阻断疗法
批准号：
486202
负责人：
Pfeil Jennifer Q
金额：
$1.27万
依托单位：
University of Toronto
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2022
资助国家：
加拿大
项目状态：
已结题
起止时间：
2022-12-01 至 2023-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=486202&lang=en
关键词：
Anti-Pd-L1 Therapy Breast Cancer Combination Therapy Immune Checkpoint Therapy Immune-Evasion Invasive Lobular Carcinoma Metastatic Disease Mouse Model Mutant Esr1 Resistant Disease

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Invasive Lobular Carcinoma (ILC) of the breast is the most common Breast Cancer subtype, which accounts for ~10% of BC cases. By ~10 years post diagnosis, ILC patients show worse survival in comparison to patients with most other subtypes, and death from
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金